Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) has released a circular calling for an Extraordinary General Meeting (EGM) on December 17, 2025. The proposals up for consideration include the adoption of an H Share Award Scheme, authorization to the board of directors or their delegates to handle relevant issues, the cancellation of the Supervisory Committee, and related amendments to the Articles of Association.
Under the proposed H Share Award Scheme, up to 10% of the company’s total issued shares (excluding any treasury shares) may be granted, and new shares allotted under the scheme will be capped at 5% of issued share capital as of the EGM date. Service Provider Participants would be subject to an additional limit of 1%. The board will be empowered to oversee the trust arrangements, vesting conditions, and funding for buying shares in accordance with the scheme’s terms.
The company also plans to cancel the current Supervisory Committee and transfer its responsibilities to the Audit Committee. In line with this change, the Articles of Association will be amended accordingly, subject to shareholders’ approval. If approved, the Supervisory Committee will be dissolved, its members will cease to hold positions, and the Audit Committee will assume the relevant supervisory duties.
The EGM notice further states that the register of members of H shares closes from December 12, 2025 to December 17, 2025 (both days inclusive). Shareholders intending to attend must ensure all transfer documents are lodged before the register closes. The board recommends voting in favor of these proposals, which it deems aligned with the company’s interests and strategic development.
Comments